Molecular Oncology
Volume 3, Issue 2 , Pages 165-170 , April 2009

Intercepting pelvic cancer in the distal fallopian tube: Theories and realities

Received 21 November 2008 ,Revised 23 January 2009 ,Accepted 26 January 2009.

References 

  1. American Cancer Society . Cancer Facts and Figures. 2007;www.cancer.org
  2. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 1995 Nov;26(11):1260–1267
  3. Bannatyne P, Russell P. Early adenocarcinoma of the fallopian tubes. A case for multifocal tumorigenesis. Diagn. Gynecol. Obstet. 1981;3:49–60
  4. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000 Jul 15;89(2):383–390
  5. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 2007 Sep 1;25(25):3985–3990
  6. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 2008 Sep 1;26(25):4160–4165
  7. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet. Gynecol. 2005 Dec;106(6):1327–1334
  8. Eifel PJ, Ross J, Hendrickson M, Cox RS, Kempson R, Martinez A. Adenocarcinoma of the endometrium. analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer. 1983 Sep 15;52(6):1026–1031
  9. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 2006 Jan;100(1):58–64
  10. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 2008 May;109(2):168–173
  11. Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin. Oncol. (R. Coll. Radiol.). 2000;12:58–59
  12. Hutson R, Ramsdale J, Wells M. P53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995 Oct;27(4):367–371
  13. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 2008 Jan;27(1):1–9
  14. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007 Feb;31(2):161–169
  15. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992 Mar 15;52(6):1622–1627
  16. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 2007 Nov;107(2):159–162
  17. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007 Jan;211(1):26–35
  18. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 2002 Oct;87(1):52–56
  19. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001 Nov;195(4):451–456
  20. Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer. 2003;2(2):73–78
  21. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 2005 Jan 1;23(1):127–132
  22. Shih I, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004 May;164(5):1511–1518
  23. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005 Feb;29(2):218–224
  24. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 1995 Nov;26(11):1268–1274
  25. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the united states. Gynecol. Oncol. 2007 Dec;107(3):392–397
  26. Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, et al. Risk factors for a serous cancer precursor (“p53 signature”) in women with inherited BRCA mutations. Gynecol. Oncol. 2008 Aug 20;
  27. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol. Oncol. 2008 Sep;110(3):408–417
  28. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 1997 Jan;150(1):177–185
  29. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am. J. Surg. Pathol. 2000 Jun;24(6):797–806
  30. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. P53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am. J. Surg. Pathol. 1998 Dec;22(12):1463–1473

PII: S1574-7891(09)00020-9

doi: 10.1016/j.molonc.2009.01.004

Molecular Oncology
Volume 3, Issue 2 , Pages 165-170 , April 2009

Article Tools

* Image Usage & Resolution